Arachidonylethanolamide - ≥98%, high purity , CAS No.94421-68-8, Channel blocker of Ca v3.1;Channel blocker of Ca v3.2;Channel blocker of Ca v3.3;Agonist of CB 1 receptor;Agonist of CB 2 receptor;Allosteric modulator of glycine receptor α1 subunit;Agonist of GPR18;Agonist of GPR55;Channel blocker of K 2P3.1;Inhibitor o

Item Number
A274932
Grouped product items
SKUSizeAvailabilityPrice Qty
A274932-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$75.90
A274932-25mg
25mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$279.90

Endogenous cannabinoid

Basic Description

SynonymsAEA | [14C]Anandamide | AEA-D8 | NAE(20:4) | NCGC00161195-05 | 5,8,11,14-Eicosatetraenamide, N-(2-hydroxyethyl)-, (all-Z)- | Arachidonic acid N-(hydroxyethyl)amide | DTXSID301017453 | HMS1989M15 | NCGC00161195-03 | SR-01000946635 | arachidonoylethanolamid
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsAn arachidonic acid derivative that is an endogenous ligand for the CB cannabinoid receptor and for the VR1 vanilloid receptor. Inhibits calcium currents in neuroblastomas and neurons. Activates the MAP kinase signaling pathway. Inhibits proliferation and
Storage TempProtected from light,Store at -20°C,Argon charged,Desiccated
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeACTIVATOR, AGONIST, ALLOSTERIC MODULATOR, CHANNEL BLOCKER, INHIBITOR
Mechanism of actionChannel blocker of Ca v3.1;Channel blocker of Ca v3.2;Channel blocker of Ca v3.3;Agonist of CB 1 receptor;Agonist of CB 2 receptor;Allosteric modulator of glycine receptor α1 subunit;Agonist of GPR18;Agonist of GPR55;Channel blocker of K 2P3.1;Inhibitor o
NoteProviding storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 6 months. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

Store at -20°C (desiccating conditions).

AI Insight

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name (5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide
INCHI InChI=1S/C22H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h6-7,9-10,12-13,15-16,24H,2-5,8,11,14,17-21H2,1H3,(H,23,25)/b7-6-,10-9-,13-12-,16-15-
InChi Key LGEQQWMQCRIYKG-DOFZRALJSA-N
Canonical SMILES CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO
Isomeric SMILES CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCO
Molecular Weight 347.543

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

9 results found

Lot NumberCertificate TypeDateItem
H2414233Certificate of AnalysisJul 26, 2024 A274932
H2414464Certificate of AnalysisJul 26, 2024 A274932
H2414466Certificate of AnalysisJul 26, 2024 A274932
H2414468Certificate of AnalysisJul 26, 2024 A274932
A2205215Certificate of AnalysisJul 12, 2023 A274932
A2205214Certificate of AnalysisJul 12, 2023 A274932
I2207232Certificate of AnalysisJun 15, 2023 A274932
I2207233Certificate of AnalysisJun 15, 2023 A274932
I2207238Certificate of AnalysisJun 15, 2023 A274932

Related Documents

Alternative Products

Reviews

Customer Reviews

References

1. Ross RA.  (2003)  Anandamide and vanilloid TRPV1 receptors..  Br J Pharmacol,  140  (5): (790-801).  [PMID:14517174] [10.1021/op500134e]
2. De Petrocellis L, Schiano Moriello A, Imperatore R, Cristino L, Starowicz K, Di Marzo V.  (2012)  A re-evaluation of 9-HODE activity at TRPV1 channels in comparison with anandamide: enantioselectivity and effects at other TRP channels and in sensory neurons..  Br J Pharmacol,  167  (8): (1643-51).  [PMID:22861649] [10.1021/op500134e]
3. Landucci E et al..  (2011)  CB1 receptors and post-ischemic brain damage: studies on the toxic and neuroprotective effects of cannabinoids in rat organotypic hippocampal slices..  Neuropharmacology,  60  (4): (674-82).  [PMID:21130785]
4. Brighton PJ et al..  (2011)  Characterization of the endocannabinoid system, CB(1) receptor signalling and desensitization in human myometrium..  Br J Pharmacol,  164  (5): (1479-94).  [PMID:21486283]
5. Kim J et al..  (2014)  Docosahexaenoyl ethanolamide improves glucose uptake and alters endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts..  Front Physiol,  (100).  [PMID:24711795]

Solution Calculators